Adverse Events of Adjuvant Mitotane Treatment for Adrenocortical Carcinoma

IF 1.5 4区医学 Q4 ENDOCRINOLOGY & METABOLISM

Endocrine Research Pub Date : 2024-09-15 DOI:10.1080/07435800.2024.2402311

Ivana Dora Vodanović, Anja Barač Nekić, Lana Šambula, Karin Zibar Tomšić, Tina Dušek, Darko Kaštelan

引用次数: 0

Abstract

Mitotane is the cornerstone of adjuvant adrenocortical cancer (ACC) treatment. However, its use is burdened with frequent adverse events.A retrospective analysis of adverse events was performed in ...

查看原文本刊更多论文

肾上腺皮质癌米托坦辅助治疗的不良事件

米托坦是肾上腺皮质癌（ACC）辅助治疗的基石。然而，米托坦在使用过程中经常出现不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Endocrine Research 医学-内分泌学与代谢

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： This journal publishes original articles relating to endocrinology in the broadest context. Subjects of interest include: receptors and mechanism of action of hormones, methodological advances in the detection and measurement of hormones; structure and chemical properties of hormones. Invitations to submit Brief Reviews are issued to specific authors by the Editors.